Four patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2035
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2041.
US 10,561,610
Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof
Jan 20, 2035
US 11,484,500
Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof
Jan 20, 2035
US 11,944,706
Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof
no later than Jan 20, 2035
US 11,634,742
Compositions of DNA Molecules, Methods of Making Therefor, and Methods of Use Thereof
Jul 26, 2041
202420282032203620402041
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
17 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jan 2035 · High confidence
Also notable
Ends Jul 2041 · High confidence
Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof
US 10,561,610
The most cited patent in this portfolio, cited by 21 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2035.
Compositions of DNA Molecules, Methods of Making Therefor, and Methods of Use Thereof
US 11,634,742
Cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 18, 2027The maintenance fee for Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof (US 10,561,610) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof (US 11,944,706) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,561,610 | Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,484,500 | Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 11,944,706 | Hybridosomes, Compositions Comprising the Same, Processes for Their Production and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 11,634,742 | Compositions of DNA Molecules, Methods of Making Therefor, and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 17 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed